Gilead Sciences (GILD)
(Delayed Data from NSDQ)
$110.86 USD
-1.68 (-1.49%)
Updated Sep 16, 2025 04:00 PM ET
After-Market: $110.90 +0.04 (0.04%) 7:58 PM ET
3-Hold of 5 3
B Value F Growth C Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
Currently, Gilead Sciences, Inc. has a PEG ratio of 0.80 compared to the Medical - Biomedical and Genetics industry's PEG ratio of 1.63.
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
GILD 110.86 -1.68(-1.49%)
Will GILD be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for GILD based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for GILD
Gilead Sciences (GILD) Exceeds Market Returns: Some Facts to Consider
Here is What to Know Beyond Why Gilead Sciences, Inc. (GILD) is a Trending Stock
GILD: What are Zacks experts saying now?
Zacks Private Portfolio Services
GILD Wins Approval for Twice-Yearly HIV Prevention Shot in the EU
GILD Stock Slips as CVS Health Excludes New HIV Drug Yeztugo
GILD Stock Up 7% Post Q2 Earnings: Should You Buy Now or Wait?
Other News for GILD
What Analysts Are Saying About Gilead Sciences Stock
GILD: JP Morgan Raises Price Target, Reaffirms Overweight Rating | GILD Stock News
Fell Below 50 Day Moving Average appears for GILD after 1.07% move
Insider Sell: Johanna Mercier Sells Shares of Gilead Sciences Inc (GILD)
Buy Recommendation for Gilead Sciences Amid Strategic Positioning and Legal Developments